论文部分内容阅读
目的 :探讨依达拉奉对慢性阻塞性肺疾病急性加重期(AECOPD)患者炎性介质、氧化应激及肺功能的影响。方法 :经肺功能确诊为Ⅱ级的AECOPD患者80例,随机分为2组即常规治疗组(A组)和依达拉奉干预组(B组)各40例,另随机选择40例肺功能正常的健康对照组(C组)。A组采用常规治疗,B组则在A组的基础上加用依达拉奉注射液30 mg+0.9%氯化钠注射液100 m L静滴每日一次,两组均连续治疗10天。A组及B组均于治疗前和治疗后第10天测定血清IL-6(白介素-6)、IL-8(白介素-8)和SOD(超氧化物歧化酶)、MDA(丙二醛),同时进行肺功能检查,并与C组进行比较。结果 :A组及B组治疗前血清IL-6、IL-8水平及MDA活性明显高于C组,SOD含量则低于C组,差异均有统计学意义;治疗后A、B两组各项检测指标较治疗前均有所改善,而B组血清IL-6、IL-8水平及MDA活性与A组相比明显下降,SOD含量则显著升高,差异均有统计学意义,A组和B组肺功能亦均较治疗前有所改善,差异均有统计学意义,并且B组优于A组,差异有统计学意义。结论 :COPD急性加重期患者体内存在炎症反应及氧化/抗氧化失衡,依达拉奉通过降低IL-6、IL-8水平和MDA含量,升高SOD活力,并改善肺功能,对COPD急性加重期患者具有抗氧化抗炎作用。
Objective: To investigate the effect of edaravone on inflammatory mediators, oxidative stress and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Eighty AECOPD patients diagnosed with grade Ⅱ pneumoconiosis were randomly divided into two groups: conventional treatment group (A group) and edaravone intervention group (B group), 40 cases were randomly selected, and 40 cases of pulmonary function Normal healthy control group (C group). Group A was treated with conventional therapy. Group B was treated with edaravone injection of 30 mg + 0.9% sodium chloride injection 100 m L once a day on the basis of group A, and both groups were treated for 10 consecutive days. Serum levels of IL-6, IL-8, SOD, MDA and MDA were measured in both groups A and B before treatment and on the 10th day after treatment. , At the same time lung function tests, and compared with the C group. Results: The levels of serum IL-6, IL-8 and MDA before treatment in group A and group B were significantly higher than those in group C, while the content of SOD was lower than that in group C, the difference was statistically significant. After treatment, Compared with before treatment, serum IL-6, IL-8 levels and MDA activity in group B were significantly decreased as compared with those in group A, while the content of SOD was significantly increased And group B lung function also improved compared with before treatment, the differences were statistically significant, and B group is superior to A group, the difference was statistically significant. Conclusion: Inflammatory reaction and oxidative / antioxidant imbalance exist in the patients with acute exacerbation of COPD. Edaravone can increase the activity of SOD and the lung function by decreasing the levels of IL-6, IL-8 and MDA, Period patients have anti-oxidant and anti-inflammatory effects.